MEKK2 mediates aberrant ERK activation in neurofibromatosis type I

Neurofibromatosis type I (NF1) is characterized by prominent skeletal manifestations caused by NF1 loss. While inhibitors of the ERK activating kinases MEK1/2 are promising as a means to treat NF1, the broad blockade of the ERK pathway produced by this strategy is potentially associated with therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Bok, Seoyeon, Shin, Dong Yeon, Yallowitz, Alisha R., Eiseman, Mark, Cung, Michelle, Xu, Ren, Li, Na, Sun, Jun, Williams, Alfred L., Scott, John E., Su, Bing, Shim, Jae-Hyuck, Greenblatt, Matthew B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658220/
https://www.ncbi.nlm.nih.gov/pubmed/33177525
http://dx.doi.org/10.1038/s41467-020-19555-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658220/
https://www.ncbi.nlm.nih.gov/pubmed/33177525
http://dx.doi.org/10.1038/s41467-020-19555-6

Ejemplares similares